Project Grant K38HL174893
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$179K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $445,000 to The Children's Hospital of Philadelphia to conduct research on the role of neutrophil extracellular traps (NETs) in thromboinflammatory diseases. The research aims to: 1) characterize the role of NETs in immune homeostasis, 2) define the mechanism by which platelet factor 4 (PF4) and an Fc-modified anti-PF4 antibody...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $445,000 in funding to The Children's Hospital of Philadelphia to study the mechanisms by which impaired mitochondrial function leads to failure of neutrophil development, and how neutrophil precursors use somatic mutations to adapt to this cell-intrinsic stress. The goal is to define the pathophysiology of severe congenital neutropenia caused by CLPB mutations...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $465,000 in funding to Bloodworks, a non-profit organization based in Seattle, WA. The award supports research into the mechanisms by which chronic inflammation disrupts hemostatic function in sickle cell disease (SCD). Specifically, the project aims to investigate how TNF-driven inflammation in SCD blocks autophagy and mitophagy in...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $765,622 to Yale University, with a sub-award to the Children's Hospital of Philadelphia, to develop orally bioavailable protein degraders targeting fetal hemoglobin gene repressors. The goal is to elevate fetal hemoglobin levels and prevent erythroid sickling to treat sickle cell disease. The award period runs from January 1, 2025 to November 30, 2028....
The National Heart Lung and Blood Institute (NHLBI) awarded a $111,626 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Colorado-Denver to investigate ways to target macrophage populations and attenuate pulmonary hypertension associated with sickle cell disease. The 2-year project aims to determine if modifying iron release from the ferroportin transporter can alter CD169+ macrophage and adaptive immune cell quantities, phenotypes, and oxidative status (Aim 1);...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $159,512 to generate a comprehensive single-cell transcriptomic and epigenomic map of human bone marrow cells and experimentally establish the mesenchymal hierarchy in human bone. The primary goals are to unravel the complex cellular signaling networks in bone marrow and provide insights into how cell fates are regulated, with the long-term aim of developing novel...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a $496,503 research study at the University of Pennsylvania Clinical Practices examining sex and gender influences on inflammation and pain in sickle cell disease (SCD). The objectives are to (1) ascertain sex- and gender-related mechanisms of perimenstrual vaso-occlusive pain episodes (VOEs) in SCD, and (2) determine the therapeutic effectiveness of the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...